18

<u>Claims</u>

1. A method for treating or preventing infection of feline immunodeficiency virus

	2	(FIV) in a feline animal, said method comprising administering to said feline animal an
	3	effective amount of azidothymidine (AZT) and another nucleoside analog.
•		
	1	2. The method according to claim_1, wherein said another nucleoside analog is
	2	3TC.
		/
	1	3. The method according to claim 1, wherein said feline animal receives bone
	2	marrow transplantation after total body intadiation.
		1
	1	4. The method according to claim 3, wherein the transplanted cells are selected
	2	from the group consisting of allogeneic cells and autologous cells.
	1	5. A method for treating or preventing infection of feline immunodeficiency virus
	2	(FIV) in a feline animal, said method comprising administering to said feline animal an
	3	effective amount of azidothymidine (AZT), another nucleoside analog and an inhibitor
	4	of a retroviral protease.
	1	6. The method according to claim 5, wherein said another nucleoside analog is
	2	3TC.
	1	7. The method according to claim 5, wherein said inhibitor of a retroviral
	2	protease is selected from the group consisting of HIV protease inhibitors and FIV
	3	protease inhibitors.
	1	8. The method according to claim 5, wherein said inhibitor of a retroviral protease
	2	is designated as HBY-793 and has the structure shown in Figure 4.

	1	9. The method according to claim 5, wherein said another nucleoside analog is
	2	3TC and said inhibitor of a retroviral protease is designated as HBY-793 and has the
	3	structure shown in Figure 4.
		/
	1	10. The method according to claim 5, wherein said feline animal receives bone
	2	marrow transplantation after total body tradiation.
		P
	1	11. The method according to claim 10, wherein the transplanted cells are selected
	2	from the group consisting of allogeneic cells and autologous cells.
15	1	12. A kit comprising in one or more containers AZT, another nucleoside analog
	2	and an inhibitor of a retroviral protease.
71		
ւր, արա այր ըրդար առաջության արագրարության արագրարության արագրարության արագրարության արագրարության արագրարությ	1	13. The kit according to claim 14, wherein said another nucleoside analog is
.]	2	3TC.
-	1	14. The kit according to claim 12, wherein said inhibitor of a retroviral protease
L.,	2	is designated as HBY-793 and has the structure shown in Figure 4.
H. B. H. 4mm 11 B. H. 4mm 11nd 11nd 11nd 11nd 11nd 11nd 11nd 11		
:=±	1	15. The kit according to claim 1/2, wherein said another nucleoside analog is 3TC
	2	and said inhibitor of a retroviral protease is designated as HBY-793 and has the structure
	3	shown in Figure 4.